M. Kneussl (Vienna, Austria), H. Ghofrani (Giessen, Germany)
Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation
H. J. Bogaard, A. Boonstra, A. Vonk Noordegraaf (Amsterdam, Netherlands)
|  |
The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD)
H. J. Bogaard, R. P. van Steenwijk, P. Bresser (Amsterdam, Netherlands)
| |
Biological markers predictors of pulmonary hypertension
C. Tanaseanu, S. Tanaseanu (Bucharest, Romania; Osaka, Japan)
| |
Intracardiac shunt measurement by MRI in patients with pulmonary arterial hypertension caused by a congenital septum defect
R. J. Roeleveld, J. T. Marcus, R. M. Berger, A. Vonk-Noordegraaf (Amsterdam, Rotterdam, Netherlands)
| |
A new method to differentiate between CTEPH and iPAH based on the pressure wave form
J. W. Lankhaar, T. J. Faes, N. Westerhof, A. Vonk-Noordegraaf (Amsterdam, Netherlands)
| |
Reduced pulmonary capillary volume (Vc) is responsable for the increased alveolar exhaled nitric oxide (CANO) in patients with progressive systemic sclerosis (PSS) and pulmonary hypertension (PH)
G. Donadoni, A. Fumagalli, L. Ferrario, E. Baldissera, M. G. Sabbadini, G. Ciboddo, F. Caligaris Cappio, G. Cremona (Milan, Italy)
| |
Pulmonary haemodynamic in patients with COPD
N. V. Yahorava, D. G. Lasyuk, H. L. Hurevich, I. M. Lapteva (Minsk, Belarus)
| |
Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension
N. Brugger, M. Beghetti, D. Tassaux, A. Battisti, P. Jolliet (Geneva, Switzerland)
| |
Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH)
C. Marini, B. Formichi, M. Emdin (Pisa, Italy)
| |
Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH)
E. Miranda, T. Pulido, M. Porres, E. Bautista, E. Santos, G. Rojas, M. L. Martinez-Guerra, J. Gotes, A. Carrillo, D. Mendoza, J. Sandoval (Mexico City, Mexico)
| |
Treatment of pulmonary hypertension due to COPD: can we really hope in better?
D. N. Tesloianu, A. I. Tesloianu, V. V. Esanu, M. Spiridon (Iasi, Romania)
| |
Clinical and hemodynamic long term efficacy of sildenafil in primary pulmonary hypertension
J. B. Thorens, J. Plojoux, J. D. Aubert (Geneva, Lausanne, Switzerland)
| |
Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes
A. Boonstra, G. Burgess, T. Parpia, A. Torbicki (Amsterdam, Netherlands; Sandwich, United Kingdom; Warsaw, Poland)
| |
Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis
H. Wilkens, U. Mack, K. Rentz, B. Weingard, G. W. Sybrecht (Homburg, Germany)
| |
Sildenafil improves health-related quality of life in pulmonary arterial hypertension (PAH) patients
J. Pepke-Zaba, M. Brown, T. Parpia, C. Gilbert, G. Burgess (Cambridge, Sandwich, United Kingdom)
| |
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
G. Burgess, J. Dingemanse, C. Mills, H. Hoogkamer, B. Witte (Sandwich, Plymouth, United Kingdom; Allschwil, Switzerland)
| |
No clinical interaction between sitaxsentan and sildenafil
T. C. Coyne, W. Kramer (Houston, North Potomac, United States Of America)
| |
Do liver function abnormalities (abLFT) with bosentan recur with sitaxsentan?
P. C. Garces, K. L. Alford, N. S. Henry, M. Cheeks, T. C. Coyne (Houston, United States Of America)
| |
Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan
D. D. Ivy, T. C. Coyne, A. Frost (Denver, Houston, United States Of America)
| |
Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD)
V. McLaughlin, R. Barst (Ann Arbor, New York, United States Of America)
| |